Desoxymethyltestosterone was invented in 1961 by Max Huffman who obtained a patent on the compound the same year.  It was described in the scientific literature in 1963.  However, it was never brought to market as a commercial drug.   Desoxymethyltestosterone was rediscovered by chemist, AAS enthusiast, and amateur bodybuilder Patrick Arnold in 2005. Arnold produced desoxymethyltestosterone and supplied it to Victor Conte of Bay Area Laboratory Co-operative (BALCO), an American nutritional supplement company and steroid supplier. 
Rob Blenkinsop, the FDA special agent who signed the 86-page affidavit, was also involved with the BALCO crackdown and was listed as a government witness in last year’s perjury trial against Tammy Thomas. In the document, Blenkinsop claims to have been involved with the execution of four search warrants in the last four months at firms “involved with the illegal distribution of misbranded and unapproved drugs being marketed as dietary supplements.”
“According to the documents, 26 of 31 products purchased by the Food and Drug Administration as part of the investigation tested positive for at least one steroid. Among the steroids found in the products were Madol, Tren, Superdrol, androstenedione, and Turinabol.”
Desoxymethyltestosterone, also known as DMT or Madol, is a designer steroid that was recently discovered to be in use by athletes to avoid drug tests. The absence of a 3-keto group makes this steroid similar in appearance to ethylestrenol. However, as DMT was undetectable in urine tests, it is unlikely that DMT converts to a 3-keto derivative although it has been shown in the literature that ethylestrenol does in fact convert, to some degree to norethandrolone. DMT is 5-alpha reduced; however, the absence of a 3-keto group makes it impossible for the enzyme 3-alpha hydroxysteroid dehydrogenase to deactivate it in skeletal muscle. This compound cannot convert to estrogen but it is likely a strong binder of SHBG and can displace estrogens which may result in increased chance of developing gynecomastia. It is also likely that this steroid is a potent inhibitor of 11-beta hydroxylase which could also play a role in the induction of gynecomastia as described elsewhere in this text. While some have claimed that this steroid will not result in reduction of natural testosterone production, this is, in fact, untrue. DMT has achieved somewhat of a cult following since it was discovered. It is fairly potent in spite of the lack of a 3-keto group and the presence of the C17 methyl group makes it toxic to the liver, but no more so than equal doses of methandrostenolone. The anabolic to androgenic ratio shows this steroid to be 12 times more anabolic compared to methyltestosterone with almost twice as much androgenic activity. This also supports the likelihood of inhibition of 11-beta hydroxylase as does a study in the literature showing increased heart weights in animals treated with DMT 1 . DMT is found in several nutritional supplements, however, as DMT is on the radar as a designer steroid, it is unlikely that these products will remain legal for very long. In fact the DEA has signaled its intentions to schedule this steroid though it has not yet been scheduled.